Enoxaparin Administration Route
Enoxaparin should be given subcutaneously for initial therapy in acute coronary syndromes, with intravenous administration reserved only for specific situations: during fibrinolytic therapy (initial bolus in patients <75 years), at the time of PCI when bridging is needed, or in treatment-naïve patients undergoing immediate PCI. 1
Primary Route: Subcutaneous
The standard route for enoxaparin is subcutaneous for the vast majority of clinical scenarios 1, 2:
- Initial therapy for ACS: 1 mg/kg subcutaneous every 12 hours 1
- VTE prophylaxis: Subcutaneous administration is standard 2
- Renal adjustment: If CrCl <30 mL/min, reduce to 1 mg/kg subcutaneous daily 1
The FDA-approved formulation explicitly states "FOR SUBCUTANEOUS INJECTION" on the packaging 2, reinforcing this as the primary intended route.
When to Use IV Route
Intravenous enoxaparin is appropriate only in these specific circumstances 1, 3:
1. With Fibrinolytic Therapy (Age-Dependent)
- Age <75 years: 30 mg IV bolus, followed 15 minutes later by 1 mg/kg subcutaneous every 12 hours 1, 3
- Age ≥75 years: NO IV bolus; start directly with 0.75 mg/kg subcutaneous every 12 hours 1, 3
2. At Time of PCI (Bridging Scenarios)
The IV route is used to "bridge" anticoagulation gaps 1, 4:
- If last subcutaneous dose was 8-12 hours ago OR only 1 subcutaneous dose given: Give 0.3 mg/kg IV 1, 4
- If last subcutaneous dose was within 8 hours: Give NO additional enoxaparin 1, 4
- Treatment-naïve patients going directly to PCI: 0.5-0.75 mg/kg IV bolus 1, 4
Critical Pitfalls to Avoid
Do NOT routinely give enoxaparin IV - this is a common error. The 2025 ACC/AHA guidelines are explicit that subcutaneous is the standard route 1.
Key timing considerations for PCI 4:
- Within 8 hours of last subcutaneous dose = adequate anticoagulation, no additional dose needed
- 8-12 hours after last dose = diminishing effect, give 0.3 mg/kg IV booster
- Beyond 12 hours = treat as treatment-naïve with full anticoagulation regimen
Avoid "stacking" - do not give UFH to patients already on therapeutic subcutaneous enoxaparin, as this significantly increases bleeding risk 4.
Evidence Quality
The 2025 ACC/AHA guidelines 1 represent the most current and authoritative source, superseding the 2008 guidelines 3 and 2011 PCI guidelines 4. These recommendations are based on Level A evidence for subcutaneous dosing in the fibrinolytic setting 3 and Level B evidence for IV bridging at PCI 4.
Research data 5, 6, 7, 8 demonstrate that while IV administration can achieve rapid anticoagulation, subcutaneous dosing provides adequate and sustained therapeutic levels for the majority of patients, with the specific IV scenarios outlined above addressing the gaps where subcutaneous alone would be insufficient.